The randomised trials discussed in this report are large, well designed, and well conducted. The short-term effects of aromatase inhibitors on disease-free survival in post-menopausal women with hormone receptor-positive early breast cancer are strong and consistent across a range of populations, agents and settings. Information about long-term effects on overall survival and adverse events is not yet available, and even with longer follow-up will be limited by unblinding and crossover in some trials. Clinical practice recommendations developed by the NBOCC* will be reviewed as additional significant evidence becomes available and revised as required.
Recommendations for Aromatase inhibitors as adjuvant endocrine therapy